References Alexopoulos CG, Rachiotis G, Valassi M, Drivas 8-Bromo-cAMP price S, Behrakis P (2005) Under-registration of occupational diseases: the Greek case. Occup Med (Lond) 55.1:64–65 Azaroff LS, Levenstein C, Wegman DH (2002) Occupational injury and illness surveillance: conceptual filters explain underreporting. Am J Public Health 92(9):1421–1429CrossRef Bäckström M, Mjörndal T (2006) A small economic inducement to stimulate increased reporting of adverse drug reactions—a way of dealing with an old problem? Eur J Clin Pharmacol 62(5):381–385CrossRef Bäckström M, Mjörndal

T, Dahlqvist R (2004) Under-reporting of serious adverse drug reactions in Sweden. Pharmacoepidemiol Drug Saf 13(7):483–487CrossRef Biddle J, Roberts K, Rosenman KD, Welch EM (1998) What percentage of workers with work-related illnesses receive workers’ compensation https://www.selleckchem.com/products/idasanutlin-rg-7388.html benefits? J Occup Environ Med 40.4:325–331 Blandin MC, Kieffer C, Lecoanet C (2002) KCLC. Occupational diseases in 15 European countries, Eurogip; 2002 Report No: Eurogip-01/E (1) Bracchi RC, Houghton

J, Woods FJ, Thomas S, Smail SA, Routledge PA (2005) A distance-learning programme in pharmacovigilance linked to educational credits is associated with improved reporting of suspected adverse drug reactions via the UK yellow card scheme. Br J Clin Pharmacol 60(2):221–223CrossRef Brissette I, Gelberg KH, Grey AJ (2006) The effect of message type on physician compliance with disease reporting requirements. Public Health Rep 121(6):703–709 Castel BAY 63-2521 manufacturer JM, Figueras A, Pedros C, Laporte JR, Capella D (2003) Stimulating adverse drug reaction reporting: effect of a drug safety bulletin and of including yellow cards in prescription pads. Drug Saf 26(14):1049–1055CrossRef Coggon D (2001) Monitoring trends in occupational illness. Occup Environ Med 58(11):691–692CrossRef Cornelissen L, van Puijenbroek E, van Grootheest K (2008) Expectations of general practitioners and specialist

doctors regarding the feedback received after reporting an adverse drug reaction. Pharmacoepidemiol Drug Saf 17(1):76–81CrossRef de Vet E, Brug J, de Nooijer J, Dijkstra Dichloromethane dehalogenase A, de Vries NK (2005) Determinants of forward stage transitions: a Delphi study. Health Educ Res 20(2):195–205CrossRef de Vet E, de Nooijer J, de Vries NK, Brug J (2007) Testing the transtheoretical model for fruit intake: comparing web-based tailored stage-matched and stage-mismatched feedback. Health Educ Res de Vos MMM, Nieuwenhuijsen K (2006) Beroepsziekte overspanning: gewogen en te licht bevonden. Tijdschrift voor Bedrijfs- en Verzekeringsgeneeskunde 14(10):452–460 Dijkstra A, De Vries H, Roijackers J, van Breukelen G (1998) Tailored interventions to communicate stage-matched information to smokers in different motivational stages. J Consult Clin Psychol 66(3):549–557CrossRef Dijkstra A, Conijn B, De Vries H (2006) A match-mismatch test of a stage model of behaviour change in tobacco smoking.